MedWatch

Goldman Sachs reduces share in Orphazyme and drops below 5 percent boundary

Orphazyme's life on the stock exchange has been hectic in recent weeks.

Photo: DAVID GRAY/REUTERS / X00503

US company Goldman Sachs has divested shares in Danish biotech firm Orphazyme, and as of June 17, owns less than 5 percent of the company, Orphazyme reported on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs